HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Further characterization of tryptophan metabolism and its dysregulation in fibroids.

AbstractOBJECTIVE:
To determine the expression of enzymes in tryptophan (Trp) catabolism in fibroids and matched myometrium and determine the effects of race and mediator complex subunit 12 gene (MED12) mutation on their expression.
DESIGN:
Experimental laboratory study.
SETTING:
Academic research laboratory.
PATIENT(S):
Women of reproductive age who underwent hysterectomy while on no hormonal medications before surgery.
INTERVENTION(S):
Fibroids and matched myometrium were obtained from patients who underwent hysterectomy from different race or ethnic groups.
MAIN OUTCOME MEASURE(S):
The expression of enzymes in the Trp catabolic pathway, tryptophan transporters, and the cytochrome P450 1B1 gene (CYP1B1) in the fibroids and matched myometrium of women from different race and ethnic groups and in tumors bearing the MED12 mutation and tumors without the mutation was determined using quantitative reverse-transcription polymerase chain reaction. The levels of serotonin, kynurenic acid (KYNA), and nicotinamide adenine dinucleotide (NAD) were determined using enzyme-linked immunosorbent assay.
RESULT(S):
In fibroids, the expression of tryptophan hydroxylase 1 (TPH1), kynurenine amino transferase (KAT)2, large neutral amino acid transporter small subunit 2 (SLC7A8), and large neutral amino acid transporter small subunit 1 (SLC7A5) messenger RNA (mRNA) was high and that of kynureninase (KYNU) and tryptophanyl-tRNA ligase (WARS1) mRNA was low, with no changes in the expression of WARS2, kynurenine formamidase (AFMID), kynurenine 3-monooxygenase (KMO), KAT1, KAT3, and KAT4 compared with that in the matched myometrium (n = 81). The expression of CYP1B1 mRNA, a marker of the activation of the aryl hydrocarbon receptor, was higher in fibroids. Tumors bearing the MED12 mutation expressed higher levels of CYP1B1 and lower levels of WARS1, KAT1, KAT3, and KAT4 mRNAs compared with tumors without the MED12 mutation. Race or ethnicity affected the expression of KYNU, with tumors from African American and Hispanic patients expressing lower levels of KYNU mRNA compared with those from Caucasian patients. We also quantified the levels of serotonin, KYNA, and NAD, which are the end products of Trp catabolism. There were no significant differences in the levels of serotonin and KYNA, whereas the levels of NAD were lower in fibroids than in the paired myometrium. This reduction in the levels of NAD was independent of race or ethnicity.
CONCLUSION(S):
In addition to the expression of tryptophan 2,3-dioxygenase or indoleamine-pyrrole 2,3-dioxygenase, there was marked dysregulation in the expression of other enzymes in the Trp metabolic pathway and Trp transporters in fibroids. Both MED12 mutation status and race or ethnicity had selective effects on the expression of the components of this pathway. Additional functional studies are necessary to establish the physiologic significance of the tryptophan degradation pathway in the pathogenesis of fibroids and its potential as a target for novel therapies.
AuthorsTsai-Der Chuang, Derek Quintanilla, Drake Boos, Omid Khorram
JournalF&S science (F S Sci) Vol. 3 Issue 4 Pg. 392-400 (11 2022) ISSN: 2666-335X [Electronic] United States
PMID35715314 (Publication Type: Journal Article)
CopyrightCopyright © 2022 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Tryptophan
  • Serotonin
  • NAD
  • Kynurenic Acid
  • RNA, Messenger
  • Amino Acid Transport Systems, Neutral
Topics
  • Humans
  • Female
  • Tryptophan (metabolism)
  • Serotonin
  • NAD (metabolism)
  • Leiomyoma (genetics)
  • Kynurenic Acid
  • RNA, Messenger (metabolism)
  • Amino Acid Transport Systems, Neutral

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: